Innovation Before Disease | The Next Frontier in Metabolic Health

Session Focus

Lustig framed the session as prevention at scale and profit, opening with an anecdote about a publisher rejecting his last book because market analysis showed every title containing the word prevention lost money. The panel examined why prevention has been commercially and clinically neglected, and what changes when a food company, a health system and an investor treat it as an opportunity rather than a cost.

The Scale of the Problem

Lustig laid out the economics. Roughly 75 percent of US healthcare dollars go to nine conditions: type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease, cancer, dementia, fatty liver disease, polycystic ovarian disease and depression. None has a cure. Treatments address symptoms rather than the underlying problem.

On GLP-1 therapies, he was direct that they belong in the toolbox but do not fix the problem. If everyone in America who qualified received one, the cost would be roughly $2.1 trillion against current national health expenditure of about $4.7 trillion, a surcharge of roughly 50 percent on what the country already spends.

His mechanistic summary of fifty years of research was that chronic metabolic disease is mitochondrial dysfunction. No current medicine reaches the mitochondria. Food does, and some foods improve mitochondrial function while others impair it.

Working with the room, he assembled the list of what impairs it: sugar, heated fats, lack of fiber, emulsifiers and petroleum dyes. Taken together, that describes ultra-processed food.

He closed the framing with the arbitrage. Ultra-processed food generates roughly $1.7 trillion, while cleaning up the consequences costs roughly $2.45 trillion. The gap is money left on the table for anyone who can solve the problem.

Why Healthcare Has Not Addressed Prevention

Joan LaRovere MD explained the structural answer. Systems were designed and heavily invested for acute rescue, and they do that exceptionally well. They were never architected for the slow accumulation that produces chronic disease.

She argued the re-architecting begins in pediatrics, in the first two decades of life, because that is where the patterns predicting the 50-year-old get set.

She offered her own training as evidence of how fast the landscape shifted. As a resident at Boston Children’s there were two categories, juvenile diabetes and adult-onset diabetes, and trainees were taught the adult form could not appear in childhood. By the early-to-mid 1990s pediatric patients were presenting with it, first observed in Native American populations and initially assumed to be genetic.

She sees pediatrics as unusually well positioned for AI-enabled early detection. A 1967 federal mandate, prompted by finding childhood-origin disease in military recruits, established regular screening, diagnostics and treatment for children. That produces longitudinal data at population scale, including growth curves and lipid panels at ages nine to eleven, and roughly half the pediatric population is covered by Medicaid or CHIP.

The opportunity is finding signal in that data, including signatures not yet recognized, to flag patients before disease develops. She suggested adding inexpensive tests such as fasting insulin and ALT, and expects new markers to emerge as the data is examined this way.

Lustig pushed the timeline earlier still, noting that developmental programming begins in utero, and that gestational diabetes raises the likelihood a child develops diabetes. He cited five-year data from the San Francisco soda tax, a 10 percent levy on each can sold, showing gestational diabetes in the city down 43 percent since implementation. His comment: an example of prevention with no money and no scale behind it.

He also noted that 93 percent of Americans manifest at least one sign of metabolic dysfunction.

Reformulating at Commercial Scale

Bahia Jaafar described the Kuwaiti Danish Dairy Company, privately held, approaching its 65th anniversary and serving Kuwaiti consumers across six generations. The company recognized that a journey begun around good products had left it producing some that were not healthy.

The work began in 2020 after the chairman encountered Lustig’s books and lectures. Two years followed in which every ingredient and finished product was assessed with a scientific team in the US supported by European scientists.

That produced the Metabolic Matrix, built on three pillars: feed the gut, protect the liver, support the brain. Anything entering production must serve at least one.

With 225 products in the range, wholesale reformulation was impractical, so the company built a separate line. The first product was a chocolate ice cream, a re-engineering of its best-selling item, developed over roughly six months with support from the Kuwait Foundation for the Advancement of Science. Chocolate was chosen deliberately, because diabetes patients want to indulge in something that will not spike insulin.

The product then went to the Dasman Diabetes Institute, one of the largest such institutes in the Gulf, for nine months of clinical testing. Patients consumed it daily while the institute tracked insulin levels. The study, reviewed with international faculty present, found insulin levels held steady and in some cases decreased. Both the Kuwait Foundation and Dasman marks now appear on the package.

The line has since grown to seven ice cream products, four drinks and roughly four dairy products including high-protein and coffee milks without added sugar. Branded Good For Me, it now represents close to 10 percent of the company’s range, and after six years it is profitable.

Jaafar was explicit about motivation. Kuwait ranks consistently first, second or third globally for obesity, and Ministry of Health studies indicate at least 20 percent of women have diabetes or pre-diabetes, passing risk to children before birth.

On reception, she described convening six ministries and public authorities for a blind tasting in 2022. The response was enthusiastic, and the Kuwait Foundation for the Advancement of Science, a government body, helped fund the work. The product launched at Dasman with ministerial, academic and scientific attendance from across the Gulf. The company now works with ministries locally to make the case to consumers that paying slightly more today reduces medical costs later.

The Investment Case for Prevention

Carter Williams framed innovation simply: it works when the new better thing is cheaper than the old bad thing. Applied to prevention, the question becomes how to make the right decision also the cheaper one.

His fund starts from a thought experiment he posed to the health system leaders in the room. Imagine a world with no chronic disease at all. What does healthcare look like economically? What happens to the economy, to daily life, to productivity? Then work backwards from there.

Thirteen years into the fund, he said, the route is understood. Roughly $15 billion has been spent across his firm and others developing the food system innovations now coming into use.

He disputes the premise that people want to eat badly, arguing the barrier is access rather than preference. His current focus is directing capital from the parties with a genuine financial stake in longer healthy lives, including insurers and pension funds.

A Systems Approach

LaRovere argued the fix requires everyone at the table simultaneously, spanning payers, clinicians, scientists and agriculture, with pediatrics as the place the earliest signals can be caught and acted on.

Key Takeaways

1. Nine chronic metabolic conditions consume roughly 75 percent of US healthcare spending, and none has a cure.

2. GLP-1 therapies cannot be the prevention answer at scale. Universal eligibility would add roughly 50 percent to national health expenditure.

3. Food is the only intervention that reaches the mitochondria. That makes the food supply the lever rather than the pharmacy.

4. Reformulation can be profitable. KDD reached profitability in six years with roughly 10 percent of its range reformulated and clinically tested.

5. Pediatrics has the data infrastructure for early detection. Mandated screening since 1967 created longitudinal records well suited to AI analysis.

6. Prevention works when it is also cheaper. The investment case depends on aligning the better choice with the less expensive one.